Company profile

Lifebit

Precision Medicine & Genomics

Company profile

About Lifebit

Lifebit is a precision medicine and genomics company that has developed the world's leading Federated Trusted Research Environment (TRE) platform. The company's technology enables secure, compliant analysis of health data at unprecedented scale—over 275 million patient records—without requiring data to move from its source. This federated approach solves critical challenges in health AI and research where data cannot be centralized due to privacy, sovereignty, or technical constraints. Lifebit's platform suite includes the Trusted Research Environment for turning data into insights, Trusted Data Lakehouse for connecting and cataloging federated data, Trusted Data Hub for querying distributed data as one, and Airlock for secure data governance and export. The company also offers Lifebit R.E.A.L. for real-time drug side effects and disease outbreak surveillance, and specialized solutions for target identification, clinical interpretation, and biomarker discovery. The platform serves multiple sectors including pharmaceutical companies, health systems, government agencies, nonprofits, and data providers. Lifebit's technology has been peer-reviewed and featured in The Lancet Oncology (2025) for enabling federated breast cancer discovery on Genomics England data. The company's approach enables data harmonization, NGS analysis, and OMOP/FHIR standardization across distributed datasets, with customers reporting that processes that normally take years can be completed in minutes. Lifebit's Trusted Data Marketplace provides access to diverse health datasets spanning cardiometabolic, central nervous system, inflammatory, and oncology conditions, supporting clinical trial optimization, patient registries, and translational research at scale.

Company description Lifebit official website

Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceX
Work at Lifebit?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • breast cancer
  • cardiometabolic diseases
  • central nervous system disorders
  • inflammatory diseases
  • oncology
  • rare diseases

Who it serves

  • Commercial Health Organizations
  • Data Providers
  • Government
  • Health Systems
  • Nonprofits
  • Pharma

Deployment & integration

Cloud Saas · Hybrid deployment with recorded integration context.

Recorded integration context: FHIR, Genomics England, NGS data pipelines, OMOP.

Geographic context

MarketsCanada · Federal Health sector · Singapore · United Kingdom · United States
Company sourceOfficial website

Company milestones

Platform expansion

Featured in The Lancet Oncology 2025 for federated breast cancer discovery. NLM Federated Data Workshop participation demonstrating years-to-minutes data harmonization capability.

Partnerships

Recorded partners

  • Federal Health agencies
  • Genomics England
  • National Library of Medicine (NLM)
  • University of Cambridge

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

Airlock

Smart, secure and compliant data export solution

Software · HybridCompany source

Lifebit R.E.A.L.

Real-time drug side effects and disease outbreak surveillance

Platform · Cloud SaaSCompany source

Trusted Clinical Environment

Platform for turning data into clinical actions

Platform · HybridCompany source

Trusted Data Factory

Automated platform for making data usable

Platform · HybridCompany source

Trusted Data Hub

Query federated data as one, instantly

Platform · HybridCompany source

Trusted Data Lakehouse

Platform for connecting and cataloging federated data

Platform · HybridCompany source

Trusted Data Marketplace

Access data from 275M+ patients

Platform · Cloud SaaSCompany source

Trusted Research Environment (TRE)

Federated platform for turning data into insights with secure, in-place analysis

Platform · HybridCompany source

Trusted TargetID

Platform for turning data into drug targets

Platform · HybridCompany source

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

27% cure rate improvement

breast cancer patients via federated discovery

0% data movement

data stays in place while compute moves to it

Minutes vs years

federated data connection and harmonization

275M+ patient scale

accessible through federated platform

Genomics England / University of Cambridge

Federated breast cancer discovery research enabling breakthrough in cancer treatment

27% cure rate improvement for breast cancer patients; study published in The Lancet Oncology 2025

National Library of Medicine (NLM) Federated Data Workshop

Federated data connection and harmonization across distributed health data sources

Minutes instead of years for data processing and harmonization through centralized, auditable workflow

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

Dr Daniella Black

Research Lead

Professor Serena Nik-Zainal

Professor, University of Cambridge

06 · Company updates

Updates from Lifebit

Recent articles published on Lifebit's official website.

No Company updates are currently listed.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

No HAIC coverage is currently linked to this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Precision Medicine & Genomics

Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon